MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2019-09-30 was 1.59%, a 44.01% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2019-03-31 was 2.46%, a 7.42% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-09-30 was 2.84%, a 40.94% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-06-30 was 2.77%, a 37.47% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 4.00%, a 14.29% increase from fiscal 2024.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.50%, a 0.00% change from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.50%, a 122.93% increase from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.57%, a 234.04% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.00% 10-K · filed 2026-03-31 | |||
| 2024-12-31 | 3.50% 10-K · filed 2025-04-15 | |||
| 2023-12-31 | 3.50% 10-K · filed 2024-03-27 | |||
| 2022-12-31 | 1.57% 10-K · filed 2024-03-27 | |||
| 2021-12-31 | 0.47% 10-K · filed 2023-03-15 | |||
| 2020-12-31 | 0.34% 10-K/A · filed 2022-03-11 | |||
| 2019-12-31 | 1.59% 10-K · filed 2021-03-29 | |||
| 2019-09-30 | 1.59% 10-Q · filed 2019-11-13 | 1.59% 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | 1.90% 10-Q · filed 2019-08-13 | |||
| 2019-03-31 | 2.46% 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | 2.29% 10-K · filed 2020-03-09 | |||
| 2018-09-30 | 2.84% 10-Q · filed 2019-11-13 | 2.29% 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | 2.77% 10-Q · filed 2019-08-13 | 2.29% 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | 2.29% 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | 1.89% 10-K · filed 2019-04-01 | |||
| 2017-09-30 | 2.02% 10-Q · filed 2018-11-09 | 1.89% 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | 2.02% 10-Q · filed 2018-08-09 | 1.89% 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | 1.93% 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | 1.14% 10-K · filed 2018-03-16 | |||
| 2016-09-30 | 1.15% 10-Q · filed 2017-11-14 | 1.14% 10-Q · filed 2017-11-14 | ||
| 2016-06-30 | 1.15% 10-Q · filed 2017-08-08 | 1.15% 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | 1.22% 10-Q · filed 2016-05-13 | |||
| 2015-12-31 | 1.34% 10-K · filed 2018-03-16 | |||
| 2015-09-30 | 1.56% 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | 1.34% 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | 1.65% 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | 1.65% 10-K · filed 2016-03-30 | |||
| 2013-12-31 | 1.85% 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |